- CVS revealed its total revenue rose by 7.6% in the four months ending October
- The firm recently sold its operations in the Netherlands and Republic of Ireland
CVS Group has upheld its annual outlook despite subdued demand in Britain, where the veterinary services industry is the subject of a major competition probe.
The Norfolk-based company, which operates around 460 practices, revealed its total revenue rose by 7.6 per cent year-on-year in the four months ending October.
It also declared adjusted earnings before nasties increased by 5.5 per cent, with its margins climbing by 19.5 per cent.
CVS has been steadily expanding its presence in Australia since the summer of last year, making multiple takeovers, including three deals involving four sites since July for a combined £9.5million.
The business recently sold its operations in the Netherlands and Republic of Ireland, citing ‘significant investment opportunities’ in Australia and capital spending in its UK operations.
While it warned that the upcoming hike in National Insurance rates will push up staff costs, the group expects this to be offset by ‘growth, efficiencies and purchasing synergies in Australia.’
Growth: Norfolk-based CVS, which operates around 460 practices, revealed its total revenue rose by 7.6 per cent year-on-year in the four months ending October
Chancellor Rachel Reeves announced in her first Budget last month that employers’ NI rates will rise by 1.2 percentage points to 15 per cent from April. CVS expects the change to cost it around £8million in the next financial year.
‘Whilst the board remains mindful of headwinds in the UK, the fundamental need for high-quality veterinary care remains strong, the expansion into Australia is progressing well, and CVS remains well positioned to deliver attractive growth,’ the company said.
CVS’s trading update comes amid a Competition and Markets Authority investigation into the UK veterinary sector.
The CMA is concerned that pet owners might be paying too much for medicines or prescriptions and that sector consolidation could be stifling competition in some areas.
Six firms – CVS, IVC, Linnaeus, Medivet, Pets at Home and VetPartners – have bought nearly a third of Britain’s 5,000 vet practices since 2013, according to the CMA.
It warned these businesses that they could be forced to sell off segments of their business, cap prescription fees, and offer compulsory information to pet owners.
Derren Nathan, head of equity research at Hargreaves Lansdown, said CVS ‘has been badly damaged’ by the probe, but under the bonnet, the company offers exposure to some strong long-term growth drivers.
‘However, until certainty emerges next year about the extent of any changes levied on business practices in the industry, the shares could remain under pressure.’
CVS Group shares rose 2.7 per cent to 843p by late Wednesday afternoon, but the CMA inquiry has contributed to their value slumping by around 49 per cent since the year started.
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
Saxo
Saxo
Get £200 back in trading fees
Trading 212
Trading 212
Free dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
This article was originally published by a www.dailymail.co.uk . Read the Original article here. .